The Evidence Hierarchy: How to Read Peptide Research

Why this is the most important lesson in the course

I'm going to make a claim I genuinely believe: if you only ever read one lesson from this course, this is the one to read.

Here's why. The peptide field has more low-quality content per square inch than almost any other area of health information. Marketers, influencers, supplement sellers, and even some clinicians make confident claims about what peptides do based on evidence that wouldn't pass muster in a freshman biology class.

The skill that separates an educated peptide user from a hopeful one is the ability to look at a claim and ask: what kind of evidence is this actually based on, and how much weight should it carry?

That's what this lesson teaches.

You won't memorize study results. You'll learn a framework for evaluating any peptide study, paper, or claim you encounter — now and forever. This framework applies to every lesson that follows. When I tell you in Lesson 6 that BPC-157 has "extensive preclinical evidence for tendon healing," you'll know exactly what that means and what it doesn't.

The hierarchy, in order

Medical evidence isn't a flat thing. Different types of studies produce different levels of confidence. The hierarchy below is the standard framework used in evidence-based medicine, ranked from weakest to strongest:

1. Anecdotal reports — "It worked for me." Single experiences, testimonials, before/after photos. No control group. No measurement. Highly susceptible to placebo, recall bias, regression to the mean, and motivated reasoning.

2. Case reports — A clinician writes up a single patient's outcome. More rigorous than an anecdote because it's documented by a professional, but still a sample of one.

3. Case series — Multiple patients, same condition, same treatment. Often retrospective. Useful for spotting patterns but can't establish cause-and-effect.

4. In vitro studies — Experiments done on isolated cells in a dish (Latin: in glass). Useful for identifying mechanisms. Almost never directly translate to whole-organism effects. Many things kill cancer cells in a petri dish — bleach, for instance.

5. In vivo animal studies — Experiments in living organisms, usually mice, rats, or dogs. Meaningful when the biology is conserved across species, but with a brutal caveat we'll cover below.

6. Observational studies in humans — Researchers watch what happens to a group of people taking (or not taking) a compound. Cohort studies, case-control studies. Better than animal data, but vulnerable to confounding — people who take the compound may differ from people who don't in ways that affect the outcome.

7. Randomized controlled trials (RCTs) — The gold standard of single-study evidence. Participants randomly assigned to treatment or control. Properly designed, this isolates the effect of the intervention from everything else.

8. Systematic reviews and meta-analyses — Researchers pool data from all the RCTs on a question, weighing each by quality and sample size. The strongest form of evidence we have.

Now here's the central reality of peptide research as of 2026: the vast majority of peptide evidence sits at levels 4-5.

Most of what we know about BPC-157, TB-500, Epitalon, MOTS-C, Humanin, Selank, and the other research peptides this course covers comes from cell studies and animal studies. The human trial data is sparse. Systematic reviews are nearly nonexistent.

This doesn't mean the field is fraudulent. It means we're at an early stage of clinical translation, and you need to know how to weigh that.

The "valley of death" — why animal data isn't enough

Here's a statistic that should be in every peptide article ever written, and almost never is.

Roughly 90% of drugs that show promise in animal studies fail when tested in humans. Of compounds that complete preclinical animal testing and proceed to Phase 1 clinical trials, only about 10% make it to FDA approval. In oncology specifically, the failure rate is even higher — less than 5% of cancer drugs that work in animals end up working in human patients.

This phenomenon is so well-documented that it has a name in the literature: the valley of death. The space between "it works in mice" and "it works in humans" is where most therapeutic candidates go to die.

The reasons are biological. Mice aren't small humans. They live 2-3 years. Their immune systems differ from ours. Their drug metabolism differs. Lab mice are typically inbred (genetically identical) and raised in controlled environments, while humans are genetically diverse and live in messy environmental conditions. A compound that fixes a disease in a genetically homogeneous, environmentally controlled mouse population frequently fails in the heterogeneous, complex reality of human patients.

What this means for peptide claims: When you read that "BPC-157 has been shown to accelerate tendon healing," the unstated context is almost always "in rats." That's a real finding. It's also not a guarantee that the same effect occurs in humans, in the same way, at the same dose. Strong preclinical evidence is a reason to be interested. It is not a reason to be certain.

This is the framing that should sit behind every peptide claim you read for the rest of your life: what level of evidence is this claim based on, and what's the historical translation rate for that level?

The four red flags

Beyond the evidence hierarchy, there are specific patterns that should trigger skepticism whenever you encounter them. These show up constantly in peptide marketing.

Red flag #1: The hidden species. Watch for confident claims about what a peptide "does" without specifying whether it does it in humans or animals. "BPC-157 reduces inflammation" is a different claim from "BPC-157 has been shown to reduce inflammation in rat models of colitis." The first sounds like a human fact. The second is what the evidence actually supports. The shorthand is everywhere, and it consistently misleads.

Red flag #2: The conflict of interest. Who funded the research? Who's publishing the claim? A 2019 analysis published in JAMA Internal Medicine found that industry-funded studies are more likely to report favorable results for the sponsor's product than independently-funded studies on the same compounds. This doesn't mean industry-funded research is worthless — many important findings come from it — but it does mean you should weight funding source as part of your evaluation. A "study" published on a peptide vendor's blog is not the same as a study published in a peer-reviewed journal by independent researchers.

Red flag #3: The protocol with no human studies cited. If a clinician or website is recommending a specific dose, frequency, and duration of a peptide, ask one question: what human study supports this specific protocol? For many of the peptides this course covers, the honest answer is "none yet." That doesn't mean the protocol is wrong, but it does mean it's based on extrapolation from animal data and clinical experience — not on validated human trials. The honest practitioners say this. The dishonest ones don't.

Red flag #4: The "research only" disclaimer paired with a dosing protocol. This is a specific marketing pattern in the peptide vendor space. A website labels its products "for research use only — not for human consumption," then publishes detailed protocols for human use with suggested doses. This is a legal fiction designed to shield the seller from regulatory action. It doesn't change what the buyer is actually doing, and it should not reassure you about the legitimacy of the product or the protocol.

How to actually read a peptide paper

When you do encounter a piece of research — a study someone references, a paper you stumble onto, a citation in a clinician's protocol — here's a five-question framework that gets you 80% of the way to a good evaluation:

1. What species? First, third, or fifth sentence of the abstract. If it's not human, this is preclinical data. Read accordingly.

2. What was the sample size? A study in 8 rats is weaker than a study in 80 rats. A trial in 12 humans is weaker than a trial in 1,200 humans. Sample size determines whether you can trust the result wasn't due to random chance.

3. Was there a control group? A study comparing treated subjects to untreated controls is dramatically more informative than a study that just describes what happened to treated subjects.

4. Who funded it? Usually disclosed at the bottom of the paper or in a section labeled "conflicts of interest" or "funding." Note it. Weight your interpretation accordingly.

5. Has it been replicated? A single study showing an effect is interesting. Three independent studies showing the same effect is moderately convincing. A systematic review of fifteen studies showing the effect is strong evidence. Most peptide claims rest on one or a few studies, often from the same research group.

You don't need to be a biostatistician to apply this framework. You just need to ask the questions.

What "promising" actually means

I'm going to use the word "promising" a lot in the lessons that follow. So let me define what I mean by it, because the word does a lot of work in this field and is often used to mean far more than it should.

When I say a peptide has "promising preclinical evidence" for something, I mean:

• Multiple independent research groups have shown the effect
• The mechanism is biologically plausible and consistent across studies
• The animal models are reasonably relevant to the human condition being claimed
• No major safety signals have emerged in the preclinical work
• It's a justified candidate for human clinical investigation

I do not mean:

• It definitely works in humans
• The dose used in mice translates directly to humans
• It's safe for unsupervised use
• The benefit will be as large in humans as in animals
• Anyone has demonstrated long-term human safety

The honest summary of the peptide field as of 2026 is that most of the compounds in this course sit somewhere between "interesting preclinical signal" and "early human evidence." That's enough to justify continued research, careful clinical use, and educated consumer interest. It's not enough to justify confident claims or expensive protocols sold to the public as proven therapies.

Holding both of these truths at once — that the field is genuinely promising AND that the evidence is genuinely preliminary — is the intellectual stance this course will train you in.